Vaxcyte

Alexandria Real Estate Equities adds biotech company Vaxcyte as a tenant at its San Carlos mega campus, signing a 10-year lease for nearly 260,000 square feet. The campus, 97.4% occupied as of September 30, 2024, offers 1.4 million square feet of future development opportunities and amenities like a fitness center and conference rooms.

Big Pharma companies like Pfizer, Johnson & Johnson, Biogen, and Novartis are focusing on new products to drive future growth amid patent cliffs and market challenges. Pfizer's Prevnar 20 holds strong market share despite competition, while J&J's Tremfya gains traction as Stelara faces biosimilar competition. Biogen's Leqembi struggles with uptake due to infrastructure challenges, and Novartis relies on new oncology drugs to offset patent expirations and price negotiations.

FDA clears digital therapeutic DaylightRX for GAD, approves updated Novavax COVID-19 vaccine, and clears Embecta's disposable insulin patch pump. Big 3 PBMs control US drug supply chain, NCPA urges CMS for PBM protection, and Cigna's Express Scripts sues FTC. FTC counters with lawsuit against 'Big 3' PBMs for insulin price inflation. Abbott's OTC Lingo CGM available, Vaxcyte announces positive data for 31-valent pneumococcal vaccine, and AI-optimized cash pricing aids pharmacies.

FDA approves FluMist for self- or caregiver-administration, Novavax updates COVID-19 vaccine, GSK reports positive data for co-administered RSV and shingles vaccines, WHO adds MVA-BN mpox vaccine to prequalification list, New England ranks as most vaccinated region, pharmacist education reduces vaccine hesitancy, and Vaxcyte announces positive data for 31-valent pneumococcal conjugate vaccine.

Novo Nordisk's liraglutide Phase III trial in children under 12 showed a 13-point increase in Likelihood of Approval (LoA) to 50% for obesity. Pfizer's maplirpacept saw its Phase Transition Success Rate (PTSR) drop after a Phase I trial termination. Vaxcyte's VAX-31 pneumonia vaccine and Atsena Therapeutics' ATSN-101 for Leber Congenital Amaurosis (LCA) both reported positive Phase I/II trial results, increasing their PTSR. Les Laboratoires Servier's oncology Phase I trial termination led to a decline in PTSR for S-64315 and S-65487 in non-Hodgkin lymphoma (NHL), acute myeloid leukaemia (AML), and multiple myeloma (MM).

Novo Nordisk's liraglutide Phase III trial in children under 12 showed a -7.4% BMI difference favoring liraglutide. Pfizer's maplirpacept saw PTSR drop after Phase I termination. Vaxcyte's VAX-31 vaccine reported positive Phase I/II data. Atsena Therapeutics's ATSN-101 in rare disease ophthalmology met all endpoints. Les Laboratoires's oncology Phase I trial was terminated.

Vaxcyte, Inc. closed a public offering of 12,087,378 shares at $103.00 each, raising ~$1.5 billion. The company develops high-fidelity vaccines for bacterial diseases using advanced synthetic techniques.

Vaxcyte, Inc. (NASDAQ: PCVX) is developing next-gen vaccines using its XpressCF platform to prevent bacterial infections, focusing on VAX-31 and VAX-24 pneumococcal vaccines. VAX-31, in Phase 1/2 trials, aims to start Phase 3 by mid-2025, potentially securing a best-in-class position in the pneumococcal vaccine market.

Athira Pharma's lead candidate, fosgonimeton, failed Phase II/III LIFT-AD trial for Alzheimer's, causing a 81% stock drop. Despite missing primary and secondary endpoints, Athira remains committed to fosgonimeton's development, citing potential benefits in specific subgroups. Full data will be presented at the CTAD Conference in Madrid.

OrsoBio raises $67M to advance weight loss drugs; Vor Bio's CRISPR-edited stem cells show success in AML therapy; Boehringer Ingelheim to test eye drug for geographic atrophy; Novartis licenses capsid from Voyager for gene therapy; Vaxcyte raises $1.3B on positive pneumococcal vaccine data.